This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
This study aimed to evaluate the cost-effectiveness of paliperidone palmitate for patients with schizophrenia, who had experienced two or more relapses (multi-episodes).
Interventions
Paliperidone palmitate long-acting injectable was compared with risperidone long-acting injectable and olanzapine pamoate long-acting injectable. Paliperidone was administered once a month, at a 75mg dose equivalent. Olanzapine was administered every two weeks at a 150mg dose, or every four weeks at a 300mg dose. Risperidone was administered every two weeks at a 37.5mg dose.
Location/setting
Sweden/secondary care.
Methods

Analytical approach:
A Markov model was developed to simulate the ongoing probabilities of not adhering, partly adhering, or fully adhering to treatment, and of relapse and hospital admission, for a cohort of multi-episode patients. The focus of the evaluation was the first treatment choice; up to four sequential choices of therapy were modelled. The time horizon was five years. The authors stated that the perspective was that of the direct medical payer, which was the Swedish health care system.
Effectiveness data:
The main treatment effectiveness data were the risk ratio of relapse, the level of adherence, side-effects (extrapyramidal symptoms, tardive dyskinesia, weight gain and diabetes), and treatment discontinuation. The risk ratio of relapse was from a published mixed-treatment comparison for some therapies, and from several published studies for the other therapies. Adherence rates by treatment and side-effect rates were from observational data. Treatment switch rates were derived from a large observational study.
Monetary benefit and utility valuations:
The utility values for the model health states were from a UK study that used the time trade-off technique on 49 patients with stable schizophrenia and 75 lay people.
Measure of benefit:
The measure of benefit was quality-adjusted life-years (QALYs) gained. Benefits were discounted at an annual rate of
